Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN060 for prevention of venous thromboembolism after unilateral total knee arthroplasty
CTR20233320Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lofacimig in venous thromboembolism (VTE), sponsored by Alphamab Oncology. Started Nov 2023; status: completed.
02
Drugs
lofacimig
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on CTR20233320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233320.